The landscape for treating eosinophilic esophagitis (EoE), a chronic and debilitating immunological disorder, is on the verge of a significant shift following the announcement of positive Phase 3 clinical trial results for Tezspire (tezepelumab). On Thursday, development partners AstraZeneca and Amgen revealed that their blockbuster antibody successfully met both co-primary and all key secondary endpoints in the CROSSING trial. This milestone marks a critical step toward Tezspire becoming the second biologic approved for the condition, potentially challenging the current market dominance held by Sanofi and Regeneron’s Dupixent.
While the companies have not yet released specific numerical data from the trial, they confirmed that the results demonstrated statistically significant and clinically meaningful improvements for patients over a one-year period. The success of the CROSSING trial suggests that Tezspire’s unique mechanism of action—targeting thymic stromal lymphopoietin (TSLP)—could provide a potent alternative for the hundreds of thousands of individuals suffering from the chronic inflammation of the esophagus that defines EoE.
Understanding Eosinophilic Esophagitis and the Unmet Medical Need
Eosinophilic esophagitis is a chronic, progressive inflammatory disease characterized by the accumulation of eosinophils, a type of white blood cell, in the lining of the esophagus. This accumulation is triggered by an overactive immune response to food or environmental allergens. As the lining of the esophagus becomes inflamed and damaged, patients experience a range of severe symptoms, most notably dysphagia (difficulty swallowing) and food impaction, where food becomes physically lodged in the throat.
The clinical burden of EoE is substantial. In the United States alone, approximately 470,000 people are estimated to live with the condition. Without effective management, the chronic inflammation can lead to the formation of strictures—permanent narrowing of the esophagus—which often necessitates emergency room visits and invasive procedures like endoscopic dilation to widen the passage.
For years, the standard of care was limited to restrictive elimination diets and the off-label use of corticosteroids, which are swallowed rather than inhaled to coat the esophageal lining. While these methods offer some relief, they often fail to address the underlying drivers of the disease or are difficult for patients to maintain long-term. The approval of Dupixent (dupilumab) in 2022 marked the first targeted biologic therapy for EoE, setting a high bar for efficacy. However, the emergence of Tezspire offers the prospect of a different biological approach for patients who may not respond optimally to existing treatments.
The CROSSING Trial: Methodology and Primary Outcomes
The Phase 3 CROSSING trial was designed as a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Tezspire in a broad patient population. The study enrolled 368 participants ranging in age from 12 to 80 years, reflecting the disease’s prevalence across both adolescent and adult demographics.
Participants were randomly assigned to one of three cohorts: a high-dose Tezspire group, a low-dose Tezspire group, or a placebo group. The medication was administered via once-monthly subcutaneous injections. The trial utilized two co-primary endpoints to measure success:
- Histologic Remission: A measurement of the esophageal eosinophil count to determine if the drug successfully reduced the cellular drivers of inflammation.
- Symptomatic Improvement: Assessing changes in swallowing difficulty using the Dysphagia Symptom Questionnaire (DSQ), a patient-reported outcome tool that tracks the frequency and severity of swallowing issues.
According to the joint statement from AstraZeneca and Amgen, Tezspire met these primary goals with high statistical significance. Furthermore, all key secondary endpoints were achieved, and the safety profile observed in the CROSSING trial was consistent with the known safety data of Tezspire in its previously approved indications. This consistency is vital for regulatory approval, as it suggests no new or unexpected adverse effects arise when treating esophageal tissue specifically.
Mechanism of Action: The Role of TSLP in Epithelial Inflammation
The scientific foundation of Tezspire lies in its ability to inhibit thymic stromal lymphopoietin (TSLP), an epithelial cytokine. TSLP is often described as a "master switch" in the inflammatory cascade. It is released by epithelial cells—the barrier cells that line the lungs, skin, and esophagus—in response to various triggers or injuries. Once released, TSLP initiates a broad downstream immune response involving multiple pathways, including Type 2 inflammation, which is a primary driver of EoE.
Unlike Dupixent, which specifically blocks the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), Tezspire acts further upstream. By blocking TSLP, Tezspire potentially exerts a broader influence over the inflammatory environment. This "upstream" approach is what Sharon Barr, AstraZeneca’s Executive Vice President of Biopharmaceuticals R&D, referred to as a "differentiated mechanism of action."
"The positive results of the Phase 3 CROSSING trial reinforce our confidence in the differentiated mechanism of action of Tezspire, which has now demonstrated clinically meaningful efficacy in a third epithelial-driven inflammatory disease," Barr stated. This differentiation is key to the drug’s competitive strategy, as it may prove effective in a wider range of patients or provide better outcomes in specific inflammatory profiles.
Market Context and Competitive Dynamics
The potential approval of Tezspire for EoE would mark its third major indication. The drug was first approved by the FDA in 2021 as a maintenance treatment for severe asthma, followed by an approval for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2023. Each of these conditions is characterized by epithelial-driven inflammation, suggesting a versatile therapeutic reach for the TSLP inhibitor.
Financial analysts are closely watching the expansion of Tezspire’s label. Matt Phipps, an analyst at William Blair, noted that the EoE market is increasingly attractive due to growing diagnosis rates and a significant portion of the patient population that remains underserved. William Blair currently models global Tezspire sales at approximately $2.7 billion for 2024, with projections rising to $3.3 billion by 2027 based solely on its current indications. An approval in EoE would likely provide a substantial boost to these long-term revenue forecasts.
The competition with Sanofi and Regeneron’s Dupixent is a central theme in the immunology sector. Dupixent is a juggernaut with nine approved indications and multi-billion-dollar annual sales. However, Phipps pointed out that Tezspire has already shown superior efficacy in some comparisons within the CRSwNP space, which also involves Type 2 inflammation. This "positive readthrough" suggests that Tezspire could be a formidable competitor in the EoE market, potentially capturing a significant share of new patient starts and those seeking alternatives to Dupixent.
The Broader Landscape of Immunology R&D
The success of Tezspire in EoE arrives at a time of intense activity in the immunology and inflammation (I&I) space. Pharmaceutical giants are aggressively pursuing new therapies for Type 2 inflammatory diseases, as evidenced by recent high-profile mergers and acquisitions.
For instance, AbbVie recently announced an $11 billion acquisition of Apogee Therapeutics, a biotech company with an early-stage antibody pipeline targeting EoE and atopic dermatitis. Other players, such as First Tracks Biotherapeutics, are also advancing clinical programs. The entry of Tezspire into the Phase 3 success category solidifies the position of AstraZeneca and Amgen at the forefront of this competitive race, likely forcing other developers to refine their clinical targets.
The partnership between Amgen and AstraZeneca is a strategic alliance where Amgen handles the initial discovery and AstraZeneca leads much of the clinical development and international commercialization. In the United States, the two companies share profits and commercialization efforts, while AstraZeneca records all sales in markets outside the U.S. This collaboration has allowed both companies to leverage their respective strengths in respiratory and immunological medicine.
Chronology and Future Outlook
The journey of Tezspire from an asthma treatment to a multi-indication biologic has been characterized by steady clinical progression:
- December 2021: FDA approval for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
- Early 2023: Expansion into chronic rhinosinusitis with nasal polyps (CRSwNP).
- August 2024: Announcement of positive Phase 3 CROSSING trial results for EoE.
Looking ahead, AstraZeneca and Amgen have indicated that they are preparing to present the full data set from the CROSSING trial at an upcoming medical meeting, likely a major gastroenterology or allergy conference. Simultaneously, they are moving to submit these data to global regulatory authorities, including the FDA and the European Medicines Agency (EMA), to seek formal label expansion.
Furthermore, the clinical program for Tezspire is not stopping at EoE. A Phase 3 trial is currently underway to evaluate the drug’s efficacy in chronic obstructive pulmonary disease (COPD), a massive market with significant unmet needs for biologic interventions. If successful in COPD, Tezspire would further cement its status as a cornerstone of the AstraZeneca and Amgen portfolios.
For patients living with eosinophilic esophagitis, the success of the CROSSING trial offers more than just a new pharmaceutical option; it represents the continued evolution of "epithelial science." As researchers gain a deeper understanding of how the body’s barrier tissues trigger chronic inflammation, the hope is that diseases like EoE can be managed more effectively, reducing the risk of permanent esophageal damage and improving the daily quality of life for those affected. The upcoming regulatory filings will be the next major milestone to watch as Tezspire moves toward its goal of becoming a standard-of-care therapy in the gastroenterology clinic.
